SCHEMBL3869010

SCHEMBL3869010

CC(Oc1ccc2ncc(-c3ccc(Cl)cc3Cl)n2n1)C1CCCNC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 6/20 0.42
PIM1 P11309 11/20 0.39
LCK P06239 1/20 0.36
RET P07949 1/20 0.36
PDGFRB P09619 1/20 0.36
FLT3 P36888 1/20 0.36
CDK7 P50613 1/20 0.36
BLK P51451 1/20 0.36
IRAK1 P51617 1/20 0.36
CCNH P51946 1/20 0.36
SRPK1 Q96SB4 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
NPC1 O15118 1/20 0.36
DYRK3 O43781 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK5 Q00535 1/20 0.36
DYRK1A Q13627 1/20 0.36
CDK5R1 Q15078 1/20 0.36
DYRK2 Q92630 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3865528 0.89 MKNK1 (0.45) MKNK1PIM1LCKRETPDGFRB
SCHEMBL3869120 0.87 MKNK1 (0.42) MKNK1PIM1LCKRETPDGFRB
SCHEMBL3869751 0.86 PIM1 (0.54) PIM1DYRK3CCNA2CDK2CDK5
SCHEMBL3871313 0.85 FYN (0.42) MKNK1PIM1DYRK3CCNA2CDK2
SCHEMBL3871531 0.84 MKNK1 (0.42) MKNK1PIM1DYRK3CCNA2CDK2
SCHEMBL3867826 0.83 MKNK1 (0.45) MKNK1
SCHEMBL3865962 0.81 MKNK1 (0.47) MKNK1PIM1DYRK3CCNA2CDK2
SCHEMBL3866891 0.81 MKNK1 (0.40) MKNK1PIM1LCKRETPDGFRB
SCHEMBL3868645 0.81 MKNK1 (0.42) MKNK1PIM1DYRK3CCNA2CDK2
SCHEMBL3869840 0.80 MKNK1 (0.43) MKNK1IRAK4DYRK3DYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653076-B2 Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-18 US disclosed
US-20090093475-A1 Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093475-A1 Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals CDK2, CDK1, MAP4K2 MKNK1 299/4885PIM1 712/4885LCK 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.